Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Shorla Oncology logo — At Shorla Oncology we develop and commercialize innovative o...

Shorla Oncology

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers.

Founded 2018 Ireland Ireland 38 employees Series B Total: $43.30M Health Care, Manufacturing +1

General Information

Company Name Shorla Oncology
Founded Year 2018
Location Ireland Ireland
Employees 38
Industries Health Care, Manufacturing, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Shorla Oncology. To contact Shorla Oncology, visit shorlaoncology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Shorla Oncology compare?

A PDF of Shorla Oncology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Shorla Oncology soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Shorla Oncology

Shorla Oncology is an Irish healthcare startup that focuses on the development and commercialization of innovative oncology drugs, particularly targeting women's and pediatric cancers. Founded in 2018, the company's mission is to address the gaps in existing cancer treatments by providing accessible, affordable, and life-saving medications to patients in need. The company's dedicated team, comprising thought leaders, clinicians, scientists, and commercial strategists, leverages extensive experience in drug development and the commercialization of niche cancer treatments to bring about a significant clinical impact. Shorla Oncology's strategic approach is to target indications where current treatments are limited, in short supply, or insufficient for the target population. In its latest funding round, the company secured a $35.00M Series B investment on October 4, 2023. The investment was led by Kurma Partners, Enterprise Ireland, and Seroba Life Sciences, signaling not only financial support but also strategic partnerships. Shorla Oncology's commitment to addressing unmet medical needs in the oncology space, combined with its strong backing from reputable investors, positions the company to make a meaningful impact in the healthcare industry and underscores its potential for future growth and success.

Business keywords: oncology drugs, cancer treatments, women's health, pediatric oncology, drug development, commercialization, unmet medical needs, clinical impact, innovation, life-saving treatments

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $35.00M 3
Kurma Partners Enterprise Ireland Seroba Life Sciences
Kurma Partners, Enterprise Ireland +1
04 Oct 2023
Series A $8.30M 2
Enterprise Ireland Seroba Life Sciences
Enterprise Ireland, Seroba Life Sciences
03 Jun 2020

Shorla Oncology Alternatives & Competitors

View All Alternatives
Shorla Oncology vs
OnQuality Pharmaceuticals Ltd.
OnQuality Pharmaceuticals Ltd. China

developing innovative drugs and drug delivery systems that improve the quality of life of oncology p...

Series A
7 employees
Biopharma, Biotechnology
Compare Shorla Oncology vs OnQuality Pharmaceuticals Ltd.
Shorla Oncology vs
Day One Biopharmaceuticals
Day One Biopharmaceuticals United States

Cancer drug development comes of age.

Post-IPO Equity
190 employees
Biopharma, Biotechnology
Compare Shorla Oncology vs Day One Biopharmaceuticals
Shorla Oncology vs
IXALTIS SA
IXALTIS SA France

DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS

Venture round
2 employees
Biopharma, Biotechnology
Also compare with: Shorla Oncology vs OnCusp Therapeutics OnCusp Therapeutics View all alternatives

FAQ About Shorla Oncology

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers.
Shorla Oncology was founded in 2018.
Shorla Oncology is headquartered in Ireland.
Shorla Oncology operates in Health Care, Manufacturing and Pharmaceutical. Its work centres on oncology drugs, cancer treatments, women's health and pediatric oncology.
Shorla Oncology has approximately 38 employees.
Shorla Oncology has completed 2 funding rounds, raising a total of $43.30M. The latest funding stage is Series B.
Top alternatives and competitors to Shorla Oncology include OnQuality Pharmaceuticals Ltd., Day One Biopharmaceuticals, IXALTIS SA, Chordia Therapeutics Inc, Akanocure Pharmaceuticals, Inc. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Shorla Oncology and OnQuality Pharmaceuticals Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Shorla Oncology, https://bouncewatch.com/company/shorla-pharma, updated 25 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes